Zepbound (tirzepatide) is Eli Lilly's dual GIP/GLP-1 receptor agonist, FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, and, since November 2024, for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Those two separate FDA approvals matter because Medicare treats them under completely different coverage rules in 2026.
CoveredUSA's guide below walks through exactly when Medicare pays for Zepbound in 2026: the new GLP-1 Bridge Program for obesity, the standard Part D pathway for sleep apnea, how Medicare Advantage plans differ, and what to do if your plan still says no. For the diabetes version of tirzepatide, see does Medicare cover Ozempic for how GLP-1 coverage compares across indications. Check Medicare Part D coverage rules for background on how the drug benefit works.
Coverage Breakdown
| Medicare Coverage Path | Covered in 2026? | Patient Cost | Key Requirement |
|---|---|---|---|
| Original Medicare Part D, standard formulary (obesity) | No, excluded by statute | Full retail cost: about $1,060 per month for the pen in 2026 with no coverage | Social Security Act §1927(d)(2)(A) bars weight-loss drugs from standard Part D |
| Medicare GLP-1 Bridge Program (obesity, KwikPen only) | Yes, since July 1, 2026 | $50 flat monthly copay; does NOT count toward the 2026 Part D out-of-pocket cap of $2,100 | Must have Part D, meet BMI/comorbidity tiers, and use the multi-dose KwikPen (vials and single-dose pens do not qualify) |
| Original Medicare Part D (obstructive sleep apnea) | Partial, plan-dependent | Varies by formulary; typical 2026 specialty-tier coinsurance of 25% to 33% of the list price before the OOP cap applies | OSA is not a statutorily excluded condition; requires the ICD-10 code G47.33 and often prior authorization |
| Medicare Advantage (obesity or sleep apnea) | Partial, plan-dependent | Some MA plans added GLP-1 coverage as a 2026 supplemental benefit with their own copay structure | MA plans may cover drugs excluded from standard Part D; check the plan's 2026 Evidence of Coverage |
| Extra Help (Low Income Subsidy) | Yes, where the plan already covers Zepbound | $12.65 brand-name copay in 2026 for full-benefit recipients at or below 150% FPL ($23,940 for an individual in 2026) | Applies to the OSA pathway or plans covering Zepbound; Bridge Program sets its own $50 rate |
Medicare Zepbound coverage by plan type, 2026. The GLP-1 Bridge Program runs from July 1, 2026 through December 31, 2027 and only applies to the Zepbound KwikPen; single-dose pens and vials are excluded from the Bridge Program's $50 rate. Source citations below.
Source: CMS Medicare GLP-1 Bridge Fact Sheet 2026, Medicare.gov Drug Coverage, FDA Zepbound Prescribing Information
Quick Answer: Diagnosis and Plan Type Both Matter
It depends on why Zepbound is prescribed and what type of Medicare coverage you have. Since July 1, 2026, the Medicare GLP-1 Bridge Program covers the Zepbound KwikPen for obesity at a flat $50 monthly copay, and that copay does not count toward the 2026 Part D out-of-pocket cap of $2,100. For obstructive sleep apnea, standard Part D plans may cover Zepbound on their own formulary because sleep apnea is not federally excluded. Medicare Advantage coverage varies by plan.
Original Medicare Part D and the Weight-Loss Drug Exclusion
Original Medicare Part D operates under Social Security Act Section 1927(d)(2)(A), a federal statute that bars Part D plans from covering drugs used for weight loss, weight gain, or anorexia. This exclusion predates GLP-1 medications entirely and applies to Zepbound (tirzepatide), Wegovy and Ozempic (semaglutide), and any other drug prescribed primarily for obesity. Congress, not the Centers for Medicare and Medicaid Services (CMS), controls this list, so CMS cannot simply add weight-loss drugs to standard Part D on its own authority.
Legislative proposals such as the TREAT Act have sought to remove the weight-loss exclusion for years but had not passed as of the 2026 plan year. Until Congress acts, the statutory bar remains in place for standard Part D formularies, which is exactly why CMS built the GLP-1 Bridge Program as a temporary workaround rather than waiting on legislation.
The 2026 Medicare GLP-1 Bridge Program for Obesity
CMS launched the Medicare GLP-1 Bridge Program on July 1, 2026, letting Part D enrollees with obesity access the Zepbound KwikPen at a flat $50 per month copay through December 31, 2027. Only the multi-dose KwikPen auto-injector formulation qualifies; the single-dose pen and Zepbound vials are not covered under the Bridge Program's $50 rate. Eligibility runs on a three-tier BMI and comorbidity scale: a BMI of 35 or higher qualifies regardless of comorbidity; a BMI of 30 or higher qualifies with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or higher; and a BMI of 27 or higher qualifies with prediabetes, a prior heart attack, a prior stroke, or peripheral artery disease.
The most important cost detail: the Bridge Program's $50 copay is structured outside the standard Part D benefit, so it does NOT count toward the 2026 Part D out-of-pocket cap of $2,100 set by the Inflation Reduction Act of 2022. Beneficiaries pay $50 every month for as long as they remain eligible and the program stays active, regardless of how much they have already spent on other Part D drugs that year.
Zepbound for Obstructive Sleep Apnea: A Separate Coverage Path
The FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity in November 2024, the first drug ever approved specifically for that condition. Because OSA is not on the Social Security Act's exclusion list, a Zepbound prescription written with the correct ICD-10 diagnosis code (G47.33 for OSA, not E66 for obesity) can be evaluated under a Part D plan's standard formulary rules rather than being automatically denied.
Not every Part D plan has added tirzepatide for OSA to its 2026 formulary, and plans that do typically place it on a specialty tier with 25% to 33% coinsurance, plus prior authorization requiring a documented sleep study and a confirmed obesity diagnosis. At list prices around $1,060 per month, that coinsurance translates to roughly $265 to $350 per month before the plan deductible and before the $2,100 out-of-pocket cap kicks in. Beneficiaries should confirm formulary status through the Medicare Plan Finder before assuming coverage.
Medicare Advantage Plans and Zepbound Coverage
Medicare Advantage plans operate under different rules than Original Medicare Part D. Because MA plans can offer supplemental benefits beyond the standard Part D formulary, some plans chose to cover Zepbound for obesity or OSA as a 2026 supplemental drug benefit even outside the Bridge Program, with their own copay or coinsurance structure. Coverage varies enormously across the more than 3,800 Medicare Advantage plans sold nationwide, so a plan in one county may cover Zepbound while a similar plan next door does not.
Medicare Advantage enrollees should request the plan's 2026 Evidence of Coverage (EOC) and search specifically for tirzepatide or Zepbound in the drug formulary and supplemental benefits sections. During the Medicare Advantage Open Enrollment Period (January 1 through March 31, 2026, one switch allowed) or the Annual Enrollment Period (October 15 through December 7, 2026, for 2027 coverage), beneficiaries can move to a plan that covers Zepbound if their current plan does not.
One point of confusion: Medigap (Medicare Supplement) policies never cover prescription drugs, including Zepbound, because Medigap only fills cost-sharing gaps in Medicare Part A (hospital coverage) and Part B (medical coverage). If you have Original Medicare with a Medigap policy, you still need a separate standalone Part D plan to access either the GLP-1 Bridge Program or standard formulary coverage for Zepbound.